FindTrial
Sign In

Biological immunotherapy in the treatment of drug - resistant tuberculosis

CIK immunotherapy in the treatment of drug - resistant tuberculosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17012369
Enrollment
Unknown
Registered
2017-08-15
Start date
2017-09-01
Completion date
Unknown
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Interventions

Group 1:CIK combined with chemotherapy
Group 2:Chemotherapy

Sponsors

The Fifth People's Hospital of Suzhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: The tuberculosis patients with Rifampicin and isoniazid-resistant and sputum-positive

Exclusion criteria

Exclusion criteria: 1. has a history of allergic history; 2. is currently a serious complication or impaired renal function (serum creatinine level = 26umolol / L) or impaired liver function (ALT and / or AST levels 2.5 times the upper limit of laboratory reference); 3. Pregnancy or lactation women; 6 According to the task group to determine the subjects suffering from not suitable for participation in this subject or may make the patient can not participate in the whole process of any disease.

Design outcomes

Primary

MeasureTime frame
CT;Sputum culture;T cell surgroup;—

Countries

China

Contacts

Public Contactxuping

The Fifth People's Hospital of Suzhou

xuping19670822@126.com13013807540

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026